In situ hybridization was used to examine effects of monocular enucleation on nicotinic acetylcholine receptor subunit cc3 mRNA in the rat dLGNand visual cortex. After 28 days postoperative, there were no significant differences in α3 mRNA density between the contralateral (deprived) and ipsilateral (non-deprived) sides. The lack of obvious effects of visual deprivation on α3 mRNA density suggests that other factors, possibly intrinsic to dLGNand visual cortex, govern the postnatal expression of α3 mRNA.

Our project was aimed at the development of novel CB1 cannabinoid receptor antagonists that may have clinical applications for the treatment of cannabinoid and psychostimulant addiction. In this study, we designed, synthesized, and established the CB1 affinity for the 1,5-diaryl-1,2,3- triazole esters, a series of 4,5-diaryl-1-substituted-1,2,3-triazole analogues and a series of 4,5- diaryl-2-substituted-1,2,3-triazoles. Our research group has been interested in the synthesis of amphibian alkaloids due to their interesting biological activities. We have recently developed a general synthetic strategy which can rapidly prepare a few amphibian alkaloids simply from the abundant natural product (-)- cocaine This strategy was first successfully applied to the synthesis of (-)-monomorine. More recently, this strategy has also been utilized in the syntheses of both of the enantiomers of cispyrrolidine 225H and (+)-gephyrotoxin 287C.

L’utilisation intensive des insecticides pour lutter contre les insectes ravageurs de culture et vecteurs demaladies, a conduit à des polémiques sur le mode d’action des insecticides. Ces polémiques sont liéesau fait que le mode d’action des insecticides, notamment des néonicotinoïdes est mal connu. Ils agissentprincipalement sur les récepteurs à l’acétylcholine (ACh) de type nicotinique (nAChR) qui jouent un rôlefondamental dans la transmission synaptique cholinergique. Bien que ces récepteurs soient bien décritschez les mammifères, très peu d’études ont évalué l’effet des néoniotinoïdes sur un récepteur natifd’insecte.Au cours de cette thèse, nous avons pour la première fois exprimé en ovocytes de xénope un récepteurhomomérique ⍺7 de blatte et étudié ces propriétés pharmacologiques vis-à-vis des néonicotinoïdes,comparativement au récepteur a7 de rat. Nos résultats révèlent un récepteur atypique qui est insensibleà l’⍺-bungarotoxine et qui n’est pas activé par les néonicotinoïdes. Ainsi, bien que les gènes codantpour les sous-unités α7 de blatte et de rat forment un groupe monophylétique distinct des autres sousunitésd’insectes et de mammifères, les récepteurs homomériques obtenus semblent avoir despropriétés pharmacologiques différentes. Parallèlement, nous avons étudié les propriétéspharmacologiques des nAChR natifs et notamment l’effet modulateur d’un pyréthrinoïde, la permethrine,sur les courants induits par le dinotefurane. Ce travail a permis d’évaluer le mode d’action d’unantiparasitaire, le Vectra 3D. Enfin, nous avons également entrepris de développer la techniqued’extraction membranaire afin de l’utiliser comme alternative pour étudier le mode d’action desinsecticides.Pour conclure, cette thèse a permis une avancée sur l’étude de la caractérisation des propriétéspharmacologiques des récepteurs nicotiniques neuronaux des insectes et sur l’étude du mode d’actiondes insecticides néonicotinoïdes. / The intensive use of insecticides against crop pests and vectors of human and animal leads to several polemics about their mode of action. All these controversies are related to the fact that the mode of action of insecticides in insects is poorly unknown, in particular neonicotinoids which act on nicotinic acetylcholine (ACh) receptors (nAChR).During this PhD thesis, we characterized for the first time the pharmacological properties of a cockroach ⍺7 homomeric receptor in a xenopus oocyte. Our results revealed that cockroach ⍺7 in an atypical receptor that is insensitive to ⍺-bungarotoxin and not activated by neonicotinoids. Cockroach and rat ⍺7 receptors which are included in the same cluster have distinct pharmacological properties. We then studied the pharmacological properties of native receptors, in particular, the modulatory effect of permethrin on dinotefuran-induced currents. This work was included in the study of Vectra 3D. We also evaluated the use of insect central nervous system membrane extraction as a strategy to study the pharmacological properties of insect native nAChRs.To conclude, this PhD contribute to the study of the pharmacological properties of insect nAChRs and the study of the mode of action of neonicotinoids insecticides.

Nicotine has multiple behavioral effects as a result of its action in the central nervous system. Nicotine strengthens the behaviors that lead to nicotine administration (primary reinforcement), and this effect of nicotine depends on mesotelencephalic systems of the brain that are critical to goal directed behavior, reward, and reinforcement. Nicotine also serves as a ‘reinforcement enhancer’ – drug administration enhances behaviors that lead to other drug and nondrug reinforcers. Although the reinforcement enhancing effects of nicotine may promote tobacco use in the face of associated negative health outcomes, the neuroanatomical systems that mediate this effect of nicotine have never been described. The ventral tegmental area (VTA) is a nucleus that serves as a convergence point in the mesotelencephalic system, plays a substantial role in reinforcement by both drug and nondrug rewards and is rich in both presynaptic and postsynaptic nicotinic acetylcholine receptors (nAChRs). Therefore, these experiments were designed to determine the role of the VTA and nAChR subtypes in the reinforcement enhancing effect of nicotine. Transiently inhibiting the VTA with a gamma amino butyric acid (GABA) agonist cocktail (baclofen and muscimol) reduced both primary reinforcement by a visual stimulus and the reinforcement enhancing effect of nicotine, without producing nonspecific suppression of activity. Intra-VTA infusions of a high concentration of mecamylamine a nonselective nAChR antagonist, or methylycaconitine, an α7 nAChR antagonist, did not reduce the reinforcement enhancing effect of nicotine. Intra-VTA infusions of a low concentration of mecamylamine and dihydro-beta-erythroidine (DHβE), a selective antagonist of nAChRs containing the *β2 subunit, attenuated, but did not abolish, the reinforcement enhancing effect of nicotine. In follow-up tests replacing systemic nicotine injections with intra-VTA infusions (70mM, 105mM) resulted in complete substitution of the reinforcement enhancing effects – increases in operant responding were comparable to giving injections of systemic nicotine. These results suggest that *β2-subunit containing nAChRs in the VTA play a role in the reinforcement enhancing effect of nicotine. However, when nicotine is administered systemically these reinforcement enhancing effects may depend on the action of nicotine at nAChRs in multiple brain nuclei.

Alzheimer’s disease is a progressive neurodegenerative disorder generally affecting people above the age of 65 years. Even though the pathophysiological hallmarks of AD were established more than a hundred years ago, there is yet to be a drug that can stop its characteristic neuronal damage. Of the five currently FDA-approved drugs, galantamine has a unique mechanism of action. Apart from being an AChE inhibitor, galantamine can effectively potentiate (positive allosteric modulator) the effect of agonists at nAChRs at concentrations lower than those required for its action as an AChE inhibitor. Perhaps the clinical benefits observed with galantamine are associated mainly with its nAChRs-PAM action and not its AChE inhibitory effect. Inhibiting AChE causes a delay in the degradation of ACh and a prolonged presence of ACh might act at either nAChRs or mAChRs. By indirectly targeting mAChRs as well, AChE inhibitors may lead to potential side effects. Hence there is a need for specific nAChR agents. The aim of this study was to identify the structural features of galantamine that contribute solely towards its a7 nAChR-PAM effect. In doing so, we wish to divorce the structural features that might be important for interacting with AChE. Using the deconstruction approach, we have synthesized structurally abbreviated analogs of galantamine. To study the probable interactions, we docked these molecules in human a7 nAChR homology models. Ultimately, it is of interest to determine which analogs retain the PAM activity of galantamine and to address that, a preliminary screening was performed with a select few analogs using the two-electrode voltage clamp technique

Ethanol causes neurotoxicity via several mechanisms at different points in the cycle of dependence, including neuroinflammation and oxidative stress during ethanol exposure as well as excitotoxicity during ethanol withdrawal. The primary therapeutic implication is that ethanol-induced neurotoxicity requires multifunctional pharmacotherapies which reduce all mechanisms. Using an innovative pharmacological high throughput screening method on a large plant extract library we discovered flavonoids with alpha7 nicotinic acetylcholine receptor (nAChR) activity. In addition to their well-known anti-inflammatory and antioxidant properties, this novel activity means they can potentially reduce excitotoxicity and therefore makes them ideal for inhibition of ethanol-induced neurotoxicity. Rhamnetin, the candidate compound, was first found to inhibit lipopolysaccharide induced inflammation in immortalized BV2 microglia, in part, via alpha7 nAChRs. We then established an in vitro model of ethanol induced-neurotoxicity using organotypic hippocampal slice cultures which incorporated both neuroinflammatory and excitotoxic components. Neuroinflammation enhanced excitotoxicity under control conditions but the reverse was observed during ethanol withdrawal. Both mechanisms are important but their interaction is not simple. Finally, rhamnetin was evaluated in this model and found to reduce neuroinflammation and excitotoxicity associated with ethanol withdrawal. In conclusion, the studies herein provide strong evidence for alpha7 nAChRs selective flavonoids as potential pharmacotherapies for the treatment of ethanol-induced neurotoxicity and further implicate neuroinflammation, excitotoxicity, and their interaction as critical mechanisms in this pathology.

Pentameric ligand-gated ion channels (pLGICs) are membrane bound receptors found in the nervous system. They are responsible for detecting neurotransmitters released from neurons and subsequently mediating responses of the cells on which they are found. Thus, pLGICs play an invaluable role in communication between cells of the nervous system and understanding their function is pivotal to understanding how the nervous system works in general. One factor which is known to mediate pLGIC function is lipids found in the membrane environment in which pLGICs are embedded. This dissertation explores the various ways in which lipids interact with and modulate the function of pLGIC. Potential mechanisms and biological consequences of this modulation will be presented and discussed within the context of our current state of knowledge of pLGIC and nervous system function.

Pentameric ligand-gated ion channels (pLGICs) are membrane bound receptors found in the nervous system. They are responsible for detecting neurotransmitters released from neurons and subsequently mediating responses of the cells on which they are found. Thus, pLGICs play an invaluable role in communication between cells of the nervous system and understanding their function is pivotal to understanding how the nervous system works in general. One factor which is known to mediate pLGIC function is lipids found in the membrane environment in which pLGICs are embedded. This dissertation explores the various ways in which lipids interact with and modulate the function of pLGIC. Potential mechanisms and biological consequences of this modulation will be presented and discussed within the context of our current state of knowledge of pLGIC and nervous system function.

Electrical stimulation of the vagus nerve attenuates tumor necrosis factor (TNF) synthesis by macrophages and reduces the systemic inflammatory response. Current evidence suggests that the α7 nicotinic acetylcholine receptor present in the celiac/superior mesenteric ganglia is a key component in vagus nerve signaling to the spleen; however, there is currently no direct anatomical evidence that the α7 receptor is present in the murine celiac/superior mesenteric ganglia. Our study addresses this deficiency by providing anatomical evidence that the α7 receptor is expressed within the celiac/superior mesenteric ganglia and splenic nerve fibers using immunohistochemistry and quantitative polymerase chain reaction (qPCR). α7 receptor mRNA is highly expressed in the celiac/superior mesenteric ganglia and at low levels in the spleen compared to the brain. Double-labeling for α7 and tyrosine hydroxylase shows that α7 receptor protein is present on noradrenergic neurons within the ganglia and prejunctionally on noradrenergic nerve fibers within the spleen. The α7 receptor in the ganglia provides a possible location for the action of α7-selective agonists, while prejunctional α7 receptor expressed on splenic nerves may induce an increase in norepinephrine release in a positive feedback system enhanced by lymphocyte-derived acetylcholine.

Catharanthine is derived from the Catharanthus roseus plant and is an analog to ibogaine, a drug that reduces opioid and alcohol withdrawal symptoms and decreases drug self-administration in both animals and humans. Catharanthine has promise to be an alternative pharmacological treatment for addiction without the adverse side effects associated with ibogaine. The objective of this study was to evaluate catharanthine’s effects on dopamine (DA) transmission in the mesolimbic DA system as well as determine its effects on both ethanol withdrawal induced anxiety and drug-seeking behaviors in mice. We hypothesized that catharanthine would inhibit evoked DA release in the nucleus accumbens (NAc) while also reducing anxiety and drug seeking behaviors in mice. We found that superfusion of catharanthine (1-100 µM) to mouse brain slices significantly inhibits evoked DA release in the NAc of the striatum in a dose dependent manner, while also slowing DA reuptake through inhibition of the dopamine transporter (DAT), measured using fast-scan cyclic voltammetry (FSCV). We also found that intraperitoneal administration of catharanthine in live mice significantly increases extracellular DA, measured via microdialysis with electrochemical detection. Catharanthine inhibition of evoked DA release was significantly reduced by the non-selective nAChR antagonist mecamylamine, the α4 nAChR antagonist dihydro-β-erythroidine hydrobromide (DhβE) and the α6 nAChR antagonist α-conotoxin MII, suggesting that catharanthine inhibits α4 and α6 nAChRs in the NAc. Iontophoresis and in-vivo data indicates that catharanthine slows DA reuptake and increases extracellular DA in the NAc through partial inhibition of DATs. Catharanthine also blocked increases in anxiety-like behavior during ethanol withdrawal in mice in the elevated plus maze. Lastly, preliminary data suggests that catharanthine increases both water and ethanol drinking in a 24-hour two-bottle choice drinking paradigm, which was contrary to our hypothesis.